Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > tariquidar

Tarquidar : Xenova Group : P-glycoprotein (P-gp) inhibitor

QLT, Inc. Discontinues Tariquidar Phase III NSCLC Trials Following Interim Analysis by the Independent Data Safety Monitoring Committee (QLT, Inc.)
Press release announcing that QLT, Inc. has stopped its current Phase III tarquidar trials in NSCLC. The decision was made following a recommendation by the Independent Data Safety Monitoring Committee (DSMC) who completed the unblinded review of the data for both ongoing trials in this indication. QLT, Inc. intends to carefully review the interim analysis in order to plan the next steps for tarquidar. [5/03]

Phase III Tariquidar Studies Beginning in Lung Cancer (
Oncology News International reports that enrollment has begun for two randomized, placebo-controlled Phase III clinical trials of tariquidar in conjunction with chemotherapy for patients with stage IIIB/IV NSCLC. The trials are testing Tariquidar's ability to increase the effectiveness of chemotherapy affected by multidrug resistance. [7/02]

Tariquidar (XR9576) (Xenova Group)
Manufacturer's site offers an explanation of how Tariquidar works to combat drug drug resistance, describes the ongoing Phase III trials in NSCLC patients, and provides references to journal articles and abstracts. [2003]

Tariquidar - Clinical Trials (


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor